Provista Health: COVID Tests Opened the Door to Other Medicare Bills

The Provista nursing homes fraud case produced $26,341,951 in default judgments against laboratory companies and their owner over Medicare claims for unnecessary respiratory testing. The government alleged that Provista Health used an offer of COVID tests to nursing homes to generate bills for other respiratory tests, including tests physicians never ordered and tests nobody performed. For someone who knew the orders, handled the samples or submitted the claims, the case turns on a familiar question: did the service billed to Medicare match what happened to the resident?

The U.S. District Court for the District of Maryland entered the judgments on July 18, 2024, after the defendants failed to defend this nursing-home fraud case. The Department of Justice announced the outcome on July 25, 2024.

How Provista Billed Medicare for Respiratory Panels

Provista’s alleged business model used COVID testing to reach nursing-home residents, then billed Medicare for a wide array of respiratory pathogen panel tests. The government’s complaint announcement explains why it challenged those bills: the beneficiaries had no symptoms of respiratory illness, and the panels tested for uncommon respiratory pathogens.

The complaint also named AMS Onsite Inc., Britton-Harr Enterprises Inc., Coastal Laboratories Inc. and Coastal Management Group Inc., alleging that they worked with Provista and their owner to carry out the schemes.

The allegation went beyond whether a physician had chosen too broad a panel. Multiple physicians denied ordering the thousands of respiratory panel tests for which Provista allegedly submitted claims naming them as the ordering provider. A physician’s name on a bill was doing work that the physician said they had never authorized.

The government also alleged claims for tests never performed. Over 300 claims put the nasal-swab collection date after the beneficiary had died. Medicare was being billed for swabs supposedly collected from residents who were already dead.

The nursing home’s testing arrangement and the laboratory’s Medicare bill sit at different points in the business. In its 1997 report Fraud and Abuse in the Health Care Market of California, the California Research Bureau explained how contractual and financial arrangements can obscure the relationship between care and payment:

The report also describes the fee-for-service incentive: provider income rises with the frequency and complexity of services. Provista’s alleged scheme shows where that incentive could lead. The offer concerned COVID testing at a nursing home. The government’s case concerned the additional tests that appeared on Medicare bills.

What Evidence Is Needed to Prove Fraud?

For the Provista testing allegations, the useful evidence connects the resident’s clinical record, the physician’s order, the sample and the actual test to the Medicare claim. Comparing the clinical record with the bill makes each disputed part of the service visible.

The business records matter alongside the clinical ones. Testing contracts and supplier accounts connect the facility’s arrangement to the company seeking payment. We use those connections to examine how a clinical service became a government bill, and who knew the account was wrong.

Provista’s case began with the government’s own analysis of Medicare claims data, according to the complaint announcement. An insider can add the part a claim does not explain: how the ordering information got there, what the laboratory actually did, and who directed the billing.

Other Laboratory Cases Expose Different Parts of the Same Gap

BestCare Laboratory Services shows why the movement of a specimen matters. The government’s complaint alleged that specimens traveled by air while BestCare billed Medicare as though technicians had driven to collect them:

The court later found that BestCare submitted false mileage-based travel claims. In that case, the claimed journey was the fiction. In Provista’s complaint, the disputed facts included the order, the test and the collection date.

The whistleblower’s complaint against LabQ Clinical Diagnostics alleged a different mismatch. Nursing-home employees had private insurance information that LabQ allegedly failed to collect or ignored, while billing their tests to the federal uninsured program. It also alleged that free testing for nursing homes bought referrals of government-payor business. Here, the facility’s bargain and the payer named on the claim were central.

In the Kan-Di-Ki laboratory settlement, the government alleged that Kan-Di-Ki, doing business as Diagnostic Laboratories and Radiology, charged nursing facilities below-cost rates for Part A services in exchange for Medicare Part B and Medi-Cal referrals. Part A generally bundles laboratory services into the facility’s payment, leaving the facility to pay its supplier. The Part B referrals in that case brought the supplier separately paid business. That referral arrangement connected the facility’s savings to the supplier’s separately billed business.

The Genexe and Immerge settlement concerned alleged genetic-testing and kickback arrangements involving screening contractors, telemedicine providers and laboratories. Contractors recruited residents at skilled nursing facilities among other locations. The person bringing testing into the building, the person ordering it and the laboratory billing for it can occupy different places in the same transaction.

What the Provista Case Shows an Insider

The strongest detail in the Provista allegations is the distance between a service described on a claim and the people who could confirm it. Physicians disputed the orders attributed to them. Collection dates contradicted whether a resident was alive. The business’s account of the testing could be checked against records outside the billing system.

If you work inside a laboratory, nursing facility or healthcare billing operation, your knowledge may connect those records to the decisions behind them. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What Happened Between the Swab and the Bill

If you know why a respiratory panel appeared on a claim without an order, a test or a living patient on the stated collection date, speak with our whistleblower experts. We work with you to build the case around that knowledge and bring in healthcare fraud whistleblower lawyers who understand laboratory billing and nursing-home testing arrangements. We stay beside you through the pursuit of a recovery, building your strongest laboratory billing whistleblower case.